DNLI Q4 2022 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M-17.8% YoY

Gross Profit

$10M100.0% margin

Operating Income

-$105M-1024.4% margin

Net Income

-$99M-959.6% margin

EPS (Diluted)

$-0.74

QoQ Revenue Growth

+188.9%

Cash Flow

Operating Cash Flow

-$73M

Free Cash Flow

-$78M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$418M

Stockholders' Equity

$1.0B

Cash & Equivalents

$218M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$13M	-17.8%
Gross Profit	$10M	$13M	-17.8%
Operating Income	-$105M	-$77M	-36.6%
Net Income	-$99M	-$75M	-31.1%